Common Equity: The sum of all common equity items.
GT Biopharma, Inc. (GTBP) had Common Equity of $5.79M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-34.45M |
|
-- |
|
-- |
|
$12.42M |
|
$-12.42M |
|
$-15.93M |
|
$-28.35M |
|
$-28.35M |
|
$-28.35M |
|
$-28.35M |
|
$-28.35M |
|
$-28.35M |
|
$-12.42M |
|
$-12.42M |
|
5.51M |
|
5.51M |
|
$-6.68 |
|
$-6.68 |
|
| Balance Sheet Financials | |
$8.11M |
|
-- |
|
-- |
|
$8.11M |
|
$2.32M |
|
-- |
|
-- |
|
$2.32M |
|
|
Common Equity |
$5.79M |
$5.79M |
|
$5.79M |
|
25.53M |
|
| Cash Flow Statement Financials | |
$-12.91M |
|
-- |
|
$15.78M |
|
$4.04M |
|
$6.91M |
|
$2.86M |
|
$0.43M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.50 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-12.91M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-490.04% |
|
-489.96% |
|
-349.79% |
|
-489.96% |
|
$0.23 |
|
$-2.34 |
|
$-2.34 |
|